Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a clinical trial to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with palbocic
| SAN FRANCISCO, Nov. 13, 2020 /PRNewswire/ -- Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a clinical trial to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. “This study with Pfizer represents continued momentum toward our goal of advancing the clinical development of OP-1250,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “We look forward to learning more about the potential of OP-1250 in combination with palbociclib in patients living with breast cancer.” Under the terms of the non-exclusive agreement, Olema is responsible for conducting the trial and Pfizer is responsible for supplying study drug. About Olema Oncology IBRANCE is a registered trademark of Pfizer.
SOURCE Olema Oncology |
View original content:
